Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells

Apoptosis

Volumn 12, Issue 8, 2007, Pages 1455-1463

  Fok, Jansina Y ^a   Mehta, Kapil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AIF; Apoptosis; Caspase; Pancreatic cancer; TG2

Indexed keywords

APOPTOSIS INDUCING FACTOR; CALCIMYCIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MOTILITY; CELL NUCLEUS MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; CALCIMYCIN; CALCIUM CHANNELS; CARCINOMA, PANCREATIC DUCTAL; CELL DEATH; CELL DIFFERENTIATION; DEOXYCYTIDINE; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IONOPHORES; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 34250827844     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-007-0079-3     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455-465
3. Verma A, Wang H, Lanavathi B et al (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66:10525-10533
4. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614-8622
5. Mehta K, Fok JY, Mangala LS (2006) Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci 11:173-185
6. Fesus L, Madi A, Balajthy Z et al (1996) Transglutaminase induction by various cell death and apoptosis pathways. Experientia 52:942-949
7. Mangala LS, Fok JY, Zorrilla-Calancha IR et al (2006) Tissue transglutaminase expression promotes cells attachment, invasion and survival in breast cancer cells. Oncogene 25:1-12
8. Fok JY, Ekmekcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493-1503
9. Joshi S, Guleria R, Pan J et al (2006) Retinoic acid receptors and tissue-tansglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25:240-247
10. Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4:140-156
11. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature's biological glues. Biochem J 368:377-396
12. Baek KJ, Kang S, Damron D et al (2001) Phospholipase C-delta1 is a guanine nucleotide exchanging factor for transglutaminase II (Galpha h) and promotes alpha 1B-adrenoreceptor-mediated GTP binding and intracellular calcium release. J Biol Chem 276:5591-5597
13. Zemskov EA, Janiak A, Hang J et al (2006) The role of tissue transglutaminase in cell-matrix interactions. Front Biosci 11:1057-1076
14. Milakovic T, Tucholski J, McCoy E et al (2004) Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 279:8715-8722
15. Herman JF, Mangala SL, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049-3058
16. Chen JS, Agarwal N, Mehta K (2002) Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 71:237-247
17. Chen JS, Konopleva M, Andreef M et al (2004) Drug resistant breast cancer MCF-7 cells are paradoxically sensitive to apoptosis. J Cell Physiol 200:223-234
18. Devarajan E, Chen J, Multani AS et al (2002) Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 20:913-920
19. Han JA, Park SC (1999) Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 125:89-95
20. Mehta K, Fok J, Miller FR et al (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10:8068-8076
21. Jiang WG, Ablin R, Douglas-Jones A et al (2003) Expression of transglutaminase in human breast cancer and their possible clinical significance. Oncol Rep 10:2039-2044
22. Antonyak MA, Miller AM, Jansen JM et al (2004) Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicine-induced apoptosis in human breast cancer cells. J Biol Chem 279:41461-41467
23. Kim DS, Park SS, Nam BH et al (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66:10936-10943
24. Mangala LS, Mehta K (2005) Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res 38:125-138
25. Tong L, Chen Z, De Paiva CS et al (2006) Transglutaminase participates in UVB-induced cell death pathways in human corneal epithelial cells. Invest Ophthalmol Vis Sci 47:4295-4301
26. Piacentini M, Farrace MG, Piredda L et al (2002) Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. J Neurochem 81:1061-1072
27. Battaglia G, Farrace MG, Mastroberardino PG et al (2006) Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders. J Neurochem Oct 25: advance publication online
28. Jaatela M, Cande C, Kroemer G (2004) Lysosome and mitochondria in the commitment to apoptosis: a potential role for cathepsin D and AIF. Cell Death Differ 2:135-136
29. Cande C, Vahsen N, Garrido C et al (2004) Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ 6:591-595
30. Pirocanac EC, Nassirpour R, Yang M et al (2002) Bax-induction gene therapy of pancreatic cancer. J Surg Res 106:346-351
31. Mann AP, Verma A, Sethi G et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of Nuclear Factor-{kappa}B in cancer cells: delineation of a novel pathway. Cancer Res 66:8788-8795
32. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309
33. Karin M, Cao Y, Greeten FR et al (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
34. Akar U, Ozpolat B, Mehta K et al (2007) Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5:241-249
35. Yuan L, Siegel M, Choi K et al (2006) Transglutaminase 2 inhibitor, KCC009, disrupts finronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 25:1-11
36. Autuori F, Farrace MG, Oliverio S et al (1998) "Tissue" transglutaminase and apoptosis. Adv Biochem Eng Biotechnol 62:129-136
37. Kroemer G, Martin SJ (2005) Caspase-independent cell death. Nat Med 11:725-730
38. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629
39. Yamaguchi H, Bhalla K, Wang HG (2003) Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res 63:1483-1489